S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NASDAQ:ALXO

ALX Oncology - ALXO Stock Forecast, Price & News

$11.08
-0.02 (-0.18%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$10.82
$11.67
50-Day Range
$9.48
$12.89
52-Week Range
$5.82
$34.42
Volume
46,608 shs
Average Volume
354,265 shs
Market Capitalization
$451.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.67

ALX Oncology MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
221.9% Upside
$35.67 Price Target
Short Interest
Bearish
24.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.89mentions of ALX Oncology in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.17) to ($3.61) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

761st out of 1,047 stocks

Pharmaceutical Preparations Industry

372nd out of 512 stocks

ALXO stock logo

About ALX Oncology (NASDAQ:ALXO) Stock

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.

Receive ALXO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ALX Oncology and its competitors with MarketBeat's FREE daily newsletter.

ALXO Stock News Headlines

ALX Oncology Announces Trials in Progress...
ALX Oncology Holdings Inc. (ALXO)
See More Headlines
Receive ALXO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ALX Oncology and its competitors with MarketBeat's FREE daily newsletter.

ALXO Company Calendar

Last Earnings
11/11/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALXO
Fax
N/A
Employees
43
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$35.67
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+221.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-83,460,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.18 million
Book Value
$7.04 per share

Miscellaneous

Free Float
20,418,000
Market Cap
$451.57 million
Optionable
Not Optionable
Beta
2.06

Key Executives

  • Dr. Corey S. Goodman Ph.D. (Age 70)
    Independent Exec. Chairman
    Comp: $84k
  • Dr. Jaume Pons Ph.D. (Age 55)
    Founder, Pres, CEO & Director
    Comp: $849.75k
  • Mr. Peter S. Garcia M.B.A.Mr. Peter S. Garcia M.B.A. (Age 60)
    Chief Financial Officer
    Comp: $634.48k
  • Ms. Shelly Pinto (Age 45)
    VP of Fin. & Chief Accounting Officer
    Comp: $508.26k
  • Dr. Sophia Randolph M.D.Dr. Sophia Randolph M.D. (Age 54)
    Ph.D., Chief Medical Officer & Director
    Comp: $634.48k
  • Dr. Michael Chang Ph.D.
    VP of Operations
  • Dr. Chris Byrd J.D.
    Ph.D., Gen. Counsel
  • Ms. Jeanne Y. Jew (Age 58)
    Chief Bus. Officer
  • Dr. Athanasios Tsiatis M.D.
    Sr. VP of Clinical Devel.
  • Dr. Lin Yeong-Liang M.D.
    M.S., Sr. VP of Drug Safety & Pharmacovigilance













ALXO Stock - Frequently Asked Questions

Should I buy or sell ALX Oncology stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ALX Oncology in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALXO shares.
View ALXO analyst ratings
or view top-rated stocks.

What is ALX Oncology's stock price forecast for 2023?

7 brokerages have issued 1-year price targets for ALX Oncology's stock. Their ALXO share price forecasts range from $16.00 to $65.00. On average, they anticipate the company's stock price to reach $35.67 in the next year. This suggests a possible upside of 221.9% from the stock's current price.
View analysts price targets for ALXO
or view top-rated stocks among Wall Street analysts.

How have ALXO shares performed in 2022?

ALX Oncology's stock was trading at $21.49 on January 1st, 2022. Since then, ALXO shares have decreased by 48.4% and is now trading at $11.08.
View the best growth stocks for 2022 here
.

When is ALX Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our ALXO earnings forecast
.

How were ALX Oncology's earnings last quarter?

ALX Oncology Holdings Inc. (NASDAQ:ALXO) issued its earnings results on Thursday, November, 11th. The company reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.13.

What other stocks do shareholders of ALX Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ALX Oncology investors own include Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Innovative Industrial Properties (IIPR), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and

When did ALX Oncology IPO?

(ALXO) raised $128 million in an IPO on Friday, July 17th 2020. The company issued 8,000,000 shares at $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor acted as the underwriters for the IPO and LifeSci Capital was co-manager.

What is ALX Oncology's stock symbol?

ALX Oncology trades on the NASDAQ under the ticker symbol "ALXO."

Who are ALX Oncology's major shareholders?

ALX Oncology's stock is owned by many different institutional and retail investors. Top institutional shareholders include Logos Global Management LP (7.29%), BlackRock Inc. (4.10%), Vanguard Group Inc. (3.46%), Eventide Asset Management LLC (2.21%), Federated Hermes Inc. (1.14%) and State Street Corp (0.94%). Insiders that own company stock include G Walmsley Graham, Jason Lettmann, Jaume Pons, Lsv Associates, Llc, Peter S Garcia, Peter S Garcia and Sophia Randolph.
View institutional ownership trends
.

How do I buy shares of ALX Oncology?

Shares of ALXO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ALX Oncology's stock price today?

One share of ALXO stock can currently be purchased for approximately $11.08.

How much money does ALX Oncology make?

ALX Oncology (NASDAQ:ALXO) has a market capitalization of $451.57 million and generates $1.18 million in revenue each year. The company earns $-83,460,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis.

How can I contact ALX Oncology?

ALX Oncology's mailing address is 866 MALCOLM ROAD SUITE 100, BURLINGAME CA, 94010. The official website for the company is www.alxoncology.com. The company can be reached via phone at 650-466-7125 or via email at peter@alxoncology.com.

This page (NASDAQ:ALXO) was last updated on 12/2/2022 by MarketBeat.com Staff